Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Lymphoma, Mantle-Cell 66Recurrence 65Lymphoma 65Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Immunoglobulin Light-chain Amyloidosis 24Carcinoma, Non-Small-Cell Lung 24Leukemia 21Hodgkin Disease 17Hematologic Neoplasms 16Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Rocuronium 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2ziprasidone 1venetoclax 1saponin QA-21V1 1perflutren 1peginesatide 1hematide 1finerenone 1empagliflozin 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Thalidomide 1Surveys and Questionnaires 1Stem Cell Transplantation 1Standard of Care 1Spironolactone 1Specimen Handling 1Simethicone 1Sevelamer 1Resistance Training 1Quillaja Saponins 1Protein Subunit Vaccines 1Practice Guidelines as Topic 1Polymorphism, Genetic 1Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency, Chronic × Bortezomib × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡